The FIGHT study included patients with locally advanced or metastatic GC who were HER2-negative and had FGFR2b overexpression (either 2+ or 3+ staining, as detected via IHC) or FGFR2 amplification (ctDNA) and received mFOLFOX6 plus bemarituzumab as first-line therapy. Here, FGFR2 is linked to gastric cancer.